Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics
AERI Price/Volume Stats
| Current price | $15.25 | 52-week high | $15.37 |
| Prev. close | $15.24 | 52-week low | $4.81 |
| Day low | $15.24 | Volume | 1,215,100 |
| Day high | $15.25 | Avg. volume | 974,748 |
| 50-day MA | $15.19 | Dividend yield | N/A |
| 200-day MA | $10.11 | Market Cap | 753.61M |
AERI Stock Price Chart Interactive Chart >
Aerie Pharmaceuticals, Inc. (AERI) Company Bio
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.
Latest AERI News From Around the Web
Below are the latest news stories about AERIE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AERI as an investment opportunity.
Durham loses public company HQ with Alcon-Aerie deal completeFormer executives at Aerie Pharmaceuticals are in line for major payouts totaling millions of dollars now that the merger with Alcon is complete. |
Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical BusinessLeveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority . |
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical BusinessGENEVA, November 22, 2022--Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business |
Aerie Pharmaceuticals last day of trading expected Nov. 18 as part of Alcon mergerAerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC). |
Needham Remains a Hold on Aerie Pharma (AERI)Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERI - Research Report) today. The company's shares opened today at $15.21.Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Cytokinetics, and Aerie Pharma. According to TipRanks, Belanger has an average return of -5.0% and a 37.76% success rate on recommended stocks. Currently, the analyst consensus on Aerie Pharma is a Hold with an average price target of $15.25.See Insiders’ Hot Stocks on TipRanks >> Based on Aerie Pharma's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $33.31 million and a GAAP net loss of $19.37 million. |
AERI Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -12.61% |
| 5-year | -61.07% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -48.04% |
| 2020 | -44.10% |
| 2019 | -33.05% |
Continue Researching AERI
Want to see what other sources are saying about Aerie Pharmaceuticals Inc's financials and stock price? Try the links below:Aerie Pharmaceuticals Inc (AERI) Stock Price | Nasdaq
Aerie Pharmaceuticals Inc (AERI) Stock Quote, History and News - Yahoo Finance
Aerie Pharmaceuticals Inc (AERI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...